Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free DSGN Stock Alerts

Design Therapeutics (DSGN) Competitors

Design Therapeutics logo
$14.10 -0.45 (-3.09%)
Closing price 04:00 PM Eastern
Extended Trading
$14.08 -0.01 (-0.11%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

DSGN vs. DNLI, ALMS, RCUS, BEAM, and GMTX

Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Denali Therapeutics (DNLI), Alumis (ALMS), Arcus Biosciences (RCUS), Beam Therapeutics (BEAM), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.

How does Design Therapeutics compare to Denali Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 23.5% of Design Therapeutics shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Design Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.

In the previous week, Denali Therapeutics had 6 more articles in the media than Design Therapeutics. MarketBeat recorded 10 mentions for Denali Therapeutics and 4 mentions for Design Therapeutics. Denali Therapeutics' average media sentiment score of 0.71 beat Design Therapeutics' score of 0.41 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Design Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Denali Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Design Therapeutics' return on equity of -33.07% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Design TherapeuticsN/A -33.07% -31.29%
Denali Therapeutics N/A -50.13%-44.20%

Design Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 17.02%. Denali Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 77.57%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Design Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Denali Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88

Design Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Design TherapeuticsN/AN/A-$69.79M-$1.20N/A
Denali Therapeutics$330.53M9.46-$512.54M-$2.97N/A

Summary

Denali Therapeutics beats Design Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Alumis?

Design Therapeutics (NASDAQ:DSGN) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Design Therapeutics had 3 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Design Therapeutics and 1 mentions for Alumis. Design Therapeutics' average media sentiment score of 0.41 beat Alumis' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Design Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alumis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

56.6% of Design Therapeutics shares are held by institutional investors. 23.5% of Design Therapeutics shares are held by insiders. Comparatively, 40.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Design Therapeutics has higher earnings, but lower revenue than Alumis. Design Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Design TherapeuticsN/AN/A-$69.79M-$1.20N/A
Alumis$24.05M125.67-$243.32M-$3.06N/A

Design Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -1,011.75%. Design Therapeutics' return on equity of -33.07% beat Alumis' return on equity.

Company Net Margins Return on Equity Return on Assets
Design TherapeuticsN/A -33.07% -31.29%
Alumis -1,011.75%-116.97%-88.43%

Design Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Alumis has a beta of -0.31, indicating that its share price is 131% less volatile than the S&P 500.

Design Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 17.02%. Alumis has a consensus target price of $38.60, suggesting a potential upside of 62.46%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Design Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Alumis
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.92

Summary

Design Therapeutics beats Alumis on 9 of the 15 factors compared between the two stocks.

How does Design Therapeutics compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, Arcus Biosciences had 10 more articles in the media than Design Therapeutics. MarketBeat recorded 14 mentions for Arcus Biosciences and 4 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.41 beat Arcus Biosciences' score of -0.03 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcus Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Design Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Design Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. Design Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$247M12.63-$353M-$3.30N/A
Design TherapeuticsN/AN/A-$69.79M-$1.20N/A

Design Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Design Therapeutics' return on equity of -33.07% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcus Biosciences-156.36% -68.97% -35.27%
Design Therapeutics N/A -33.07%-31.29%

Arcus Biosciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500.

Arcus Biosciences presently has a consensus target price of $33.11, suggesting a potential upside of 33.50%. Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 17.02%. Given Arcus Biosciences' higher possible upside, equities research analysts clearly believe Arcus Biosciences is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64
Design Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Summary

Design Therapeutics beats Arcus Biosciences on 9 of the 15 factors compared between the two stocks.

How does Design Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, Beam Therapeutics had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 4 mentions for Design Therapeutics. Beam Therapeutics' average media sentiment score of 0.57 beat Design Therapeutics' score of 0.41 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Design Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Design Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$139.74M23.14-$79.99M-$1.01N/A
Design TherapeuticsN/AN/A-$69.79M-$1.20N/A

Design Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -57.24%. Beam Therapeutics' return on equity of -30.65% beat Design Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-57.24% -30.65% -23.73%
Design Therapeutics N/A -33.07%-31.29%

Beam Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500.

Beam Therapeutics presently has a consensus target price of $47.17, suggesting a potential upside of 49.88%. Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 17.02%. Given Beam Therapeutics' higher possible upside, equities research analysts clearly believe Beam Therapeutics is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.71
Design Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Summary

Beam Therapeutics beats Design Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Design Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, Design Therapeutics had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for Design Therapeutics and 1 mentions for Gemini Therapeutics. Design Therapeutics' average media sentiment score of 0.41 beat Gemini Therapeutics' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gemini Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Design Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/A-$71.87M-$1.00N/A
Design TherapeuticsN/AN/A-$69.79M-$1.20N/A

Design Therapeutics' return on equity of -33.07% beat Gemini Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gemini TherapeuticsN/A -38.78% -35.88%
Design Therapeutics N/A -33.07%-31.29%

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 17.02%. Given Design Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Design Therapeutics is more favorable than Gemini Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gemini Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Design Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Summary

Design Therapeutics beats Gemini Therapeutics on 12 of the 14 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DSGN vs. The Competition

Export
MetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$908.75M$3.45B$6.31B$12.15B
Dividend YieldN/A2.23%2.77%5.24%
P/E Ratio-11.7533.4528.7027.01
Price / SalesN/A293.76528.4777.56
Price / CashN/A126.4843.6254.08
Price / Book4.047.329.876.89
Net Income-$69.79M$23.57M$3.54B$333.00M
7 Day Performance3.68%2.80%1.57%1.87%
1 Month Performance15.38%6.24%6.13%8.64%
1 Year Performance327.01%79.28%43.01%43.19%

Design Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DSGN
Design Therapeutics
2.1718 of 5 stars		$14.10
-3.1%		$16.50
+17.0%		+300.6%$908.75MN/AN/A40
DNLI
Denali Therapeutics
3.0139 of 5 stars		$20.06
+0.6%		$35.00
+74.5%		+46.2%$3.16B$330.53MN/A430
ALMS
Alumis
2.0225 of 5 stars		$24.02
-2.9%		$38.60
+60.7%		+485.8%$3.15B$24.05MN/AN/A
RCUS
Arcus Biosciences
2.2369 of 5 stars		$24.73
-0.9%		$32.44
+31.2%		+222.0%$3.13B$247MN/A500
BEAM
Beam Therapeutics
2.8413 of 5 stars		$30.56
+4.8%		$49.36
+61.5%		+102.9%$3.00B$139.74MN/A510

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DSGN) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel